Cynata Therapeutics Limited
CYYNF
$0.118
$0.01615.69%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 1.15M | 1.34M | 1.51M | 1.54M | 1.56M |
| Total Revenue | 1.15M | 1.34M | 1.51M | 1.54M | 1.56M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.15M | 1.34M | 1.51M | 1.54M | 1.56M |
| SG&A Expenses | 446.10K | 935.50K | 1.39M | 1.36M | 1.30M |
| Depreciation & Amortization | 182.70K | 183.90K | 184.10K | 184.70K | 186.30K |
| Other Operating Expenses | 963.70K | 951.30K | 931.70K | 1.08M | 1.23M |
| Total Operating Expenses | 7.31M | 7.79M | 8.22M | 9.62M | 11.10M |
| Operating Income | -6.16M | -6.45M | -6.71M | -8.08M | -9.53M |
| Income Before Tax | -5.84M | -6.13M | -6.39M | -7.72M | -9.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.84 | -6.13 | -6.39 | -7.72 | -9.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.84M | -6.13M | -6.39M | -7.72M | -9.12M |
| EBIT | -6.16M | -6.45M | -6.71M | -8.08M | -9.53M |
| EBITDA | -5.97M | -6.26M | -6.53M | -7.90M | -9.35M |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | -0.03 | -0.03 | -0.04 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 728.21M | 723.37M | 718.53M | 685.64M | 652.76M |
| Average Diluted Shares Outstanding | 728.21M | 723.37M | 718.53M | 685.64M | 652.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |